K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011

被引:8
作者
Ruiz-Candelaria, Yelitza [1 ]
Miranda-Diaz, Christine [1 ]
Hunter-Mellado, Robert F. [1 ]
机构
[1] Univ Cent Caribe, Sch Med, Canc Res Unit, Bayamon, PR 00960 USA
关键词
Colorectal cancer; KRAS mutation; Hispanics; KRAS MUTATIONS; SURVIVAL; THERAPY; GENE;
D O I
10.5301/JBM.5000043
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The frequency of K-RAS mutations ranges between 30% and 48% among the Caucasian, Asian, and European populations and these mutations are predictors of response to EGFR therapies. We sought to determine the expression of K-RAS gene mutations among colorectal cancer patients in PuertoRico. A retrospective study was conducted to determine the expression of mutant K-RAS among colorectal cancer patients in Puerto Rico between April 2009 and January 2011. The mutant expression of K-RAS was found in 39% (n=195) of the Puerto Rican population, and was more common in the age group of 51-69 years (53.8%) and in males (55.4%, p>0.05). Moreover, mutant K-RAS was more commonly found in tumors of the proximal area (43.8%; p=0.03), with distant metastasis (43.3%, p=0.018), with a mucinous histotype (31.7% p>0.05), and in ulcerated tumors (38.8%, p>0.05). K-RAS mutations were observed on codon 12 (87.7%) and codon 13 (12.3%). The most frequent mutation on codon 12 was 12 ASP (39.5%), followed by 12 VAL (25.4%) that is associated with a significant decrease in overall cancer survival. The mutant expression of K-RAS in cases of rectum carcinoma was 39.5%, where the most common mutation was 12 VAL (37.5%). The frequency of K-RAS mutations in the Puerto Rican population here studied was 39% and mutant K-RAS was associated with advanced colorectal cancer stage, mucinous histotype, and ulcerated tumors.
引用
收藏
页码:E393 / E397
页数:5
相关论文
共 20 条
[1]   Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype [J].
Bazan, V ;
Migliavacca, M ;
Zanna, I ;
Tubiolo, C ;
Grassi, N ;
Latteri, MA ;
La Farina, M ;
Albanese, I ;
Dardanoni, G ;
Salerno, S ;
Tomasin, RM ;
Labianca, R ;
Gebbia, N ;
Russo, A .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1438-1446
[2]   Association of k-ras mutational status and clinical outcomes in patients with metastatic colorectal. cancer receiving panitumumab alone [J].
Freeman, Daniel J. ;
Juan, Todd ;
Reiner, Maureen ;
Hecht, J. Randolph ;
Meropol, Neal J. ;
Berlin, Jordan ;
Mitchell, Edith ;
Sarosi, Ildiko ;
Radinsky, Robert ;
Amado, Rafael G. .
CLINICAL COLORECTAL CANCER, 2008, 7 (03) :184-190
[3]   KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment [J].
Licar, Alenka ;
Cerkovnik, Petra ;
Ocvirk, Janja ;
Novakovic, Srdjan .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (05) :1137-1144
[4]   KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].
Lievre, Astrid ;
Bachet, Jean-Baptiste ;
Boige, Valerie ;
Cayre, Anne ;
Le Corre, Delphine ;
Buc, Emmanuel ;
Ychou, Marc ;
Bouche, Olivier ;
Landi, Bruno ;
Louvet, Christophe ;
Andre, Thierry ;
Bibeau, Frederic ;
Diebold, Marie-Daniele ;
Rougier, Philippe ;
Ducreux, Michel ;
Tomasic, Gorana ;
Emile, Jean-Francois ;
Penault-Llorca, Frederique ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379
[5]  
Monzon FA, 2009, ARCH PATHOL LAB MED, V133, P1600, DOI 10.1043/1543-2165-133.10.1600
[6]   KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial [J].
Richman, Susan D. ;
Seymour, Matthew T. ;
Chambers, Philip ;
Elliott, Faye ;
Daly, Catherine L. ;
Meade, Angela M. ;
Taylor, Graham ;
Barrett, Jennifer H. ;
Quirke, Philip .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :5931-5937
[7]  
Sameer A. S., 2009, Indian Journal of Cancer, V46, P219, DOI 10.4103/0019-509X.52956
[8]  
Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193
[9]   Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer [J].
Siena, Salvatore ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Balfour, Julia ;
Bardelli, Alberto .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (19) :1308-1324
[10]   The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients [J].
Sohn, Byeong Seok ;
Kim, Tae Won ;
Lee, Jae-Lyun ;
Ryu, Min-Hee ;
Chang, Heung Moon ;
Kang, Yoon-Koo ;
Park, Hyo Suk ;
Na, Young-Soon ;
Jang, Se Jin ;
Kim, Jin Cheon ;
Lee, Jung Shin .
ONCOLOGY, 2009, 77 (3-4) :224-230